NASDAQ:BCLI Brainstorm Cell Therapeutics (BCLI) Stock Price, News & Analysis $0.79 +0.02 (+3.00%) As of 02:44 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsTrendsBuy This Stock About Brainstorm Cell Therapeutics Stock (NASDAQ:BCLI) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get BCLI alerts:Sign Up Key Stats Today's Range$0.77▼$0.8550-Day Range$0.62▼$0.9552-Week Range$0.46▼$1.33Volume9,106 shsAverage Volume16,406 shsMarket Capitalization$8.75 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingHold Company Overview BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI) is a clinical‐stage biotechnology company focused on developing autologous cell therapies for the treatment of neurodegenerative diseases. The company’s proprietary platform leverages mesenchymal stem cells (MSCs) that are engineered to secrete neurotrophic and growth factors designed to support neuronal survival and function. The company’s lead product candidate, NurOwn, is an autologous MSC therapy currently in advanced clinical development for amyotrophic lateral sclerosis (ALS). NurOwn has received orphan drug designations in multiple jurisdictions and is being evaluated in a pivotal clinical program. In addition to ALS, BrainStorm is exploring potential applications of its cell therapy platform in other neurodegenerative disorders such as multiple sclerosis and Parkinson’s disease. Founded in 2000 and headquartered in Petach Tikva, Israel, BrainStorm maintains research and development operations as well as a current good manufacturing practice (cGMP) cell‐processing facility. The company also operates an office in New York City, facilitating collaborations with U.S. clinical sites and regulatory agencies. This infrastructure supports late‐stage trials and positions BrainStorm for potential commercial supply should regulatory approval be achieved. BrainStorm collaborates with leading academic institutions and regulatory authorities to advance its clinical pipeline while maintaining robust data transparency. Guided by a management team with expertise in regenerative medicine, neurology and biopharmaceutical development, the company aims to address significant unmet medical needs in the global neurodegenerative disease market.AI Generated. May Contain Errors. Read More Brainstorm Cell Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks2nd Percentile Overall ScoreBCLI MarketRank™: Brainstorm Cell Therapeutics scored higher than 2% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion1.0 / 5Analyst RatingHold Consensus RatingBrainstorm Cell Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, no buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageBrainstorm Cell Therapeutics has received no research coverage in the past 90 days.Read more about Brainstorm Cell Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Brainstorm Cell Therapeutics are expected to grow in the coming year, from ($3.01) to ($1.60) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Brainstorm Cell Therapeutics is -0.23, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Brainstorm Cell Therapeutics is -0.23, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about Brainstorm Cell Therapeutics' valuation and earnings. Short InterestN/AShort Interest LevelN/A Short InterestThere is no current short interest data available for BCLI. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldBrainstorm Cell Therapeutics does not currently pay a dividend.Dividend GrowthBrainstorm Cell Therapeutics does not have a long track record of dividend growth. News and Social Media0.0 / 5News Sentiment0.00 News Coverage This WeekMarketBeat has tracked 4 news articles for Brainstorm Cell Therapeutics this week, compared to 0 articles on an average week. Company Ownership0.6 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Brainstorm Cell Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders11.15% of the stock of Brainstorm Cell Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions14.33% of the stock of Brainstorm Cell Therapeutics is held by institutions.Read more about Brainstorm Cell Therapeutics' insider trading history. Receive BCLI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Brainstorm Cell Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. BCLI Stock News HeadlinesBrainstorm Cell Therapeutics (NASDAQ:BCLI) Stock Crosses Above 200 Day Moving Average - What's Next?June 3 at 2:13 AM | americanbankingnews.comBrainStorm Cell Therapeutics Announces Publication Calling for Updated FDA Approaches to ALS, Rare Diseases and Regenerative MedicineJune 2 at 9:00 AM | prnewswire.comTrump’s secret China dealTrump just returned from Beijing with the most powerful business delegation in American history - Elon Musk, Jensen Huang, Tim Cook, and the CEOs of BlackRock, Goldman Sachs, and CitiBank. The media covered the handshakes. But what was really being negotiated behind closed doors? Porter Stansberry has connected the Beijing trip to a landmark pact signed by 13 nations in Washington - a pact designed to cut China out of a $3 trillion investment wave tied to the most critical resource of the 21st century. His new documentary exposes the five assets at the center of it all.June 4 at 1:00 AM | Porter & Company (Ad)BrainStorm Cell Therapeutics Inc.: BrainStorm Cell Therapeutics Appoints Former FDA Associate Commissioner Peter J. Pitts to Board of DirectorsMay 28, 2026 | finanznachrichten.deBrainStorm Adds Former FDA Leader to BoardMay 28, 2026 | tipranks.comBrainStorm Cell Therapeutics Appoints Former FDA Associate Commissioner Peter J. Pitts to Board of DirectorsMay 28, 2026 | prnewswire.comBrainStorm Cell Therapeutics Announces Aggregate of $400,000 in Private Placements Priced at Premium to MarketMay 19, 2026 | prnewswire.comBrainStorm Cell Therapeutics Inc.: BrainStorm Cell Therapeutics Announces First Quarter 2026 Financial Results and Provides Corporate UpdateMay 16, 2026 | finanznachrichten.deSee More Headlines BCLI Stock Analysis - Frequently Asked Questions How have BCLI shares performed this year? Brainstorm Cell Therapeutics' stock was trading at $0.5530 at the beginning of the year. Since then, BCLI stock has increased by 39.2% and is now trading at $0.77. How were Brainstorm Cell Therapeutics' earnings last quarter? Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) posted its quarterly earnings results on Thursday, May, 15th. The biotechnology company reported ($0.45) earnings per share for the quarter, missing the consensus estimate of ($0.38) by $0.07. Read the conference call transcript. When did Brainstorm Cell Therapeutics' stock split? Brainstorm Cell Therapeutics's stock reverse split on the morning of Tuesday, October 1st 2024.The 1-15 reverse split was announced on Thursday, September 26th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Monday, September 30th 2024. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split. How do I buy shares of Brainstorm Cell Therapeutics? Shares of BCLI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Brainstorm Cell Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Brainstorm Cell Therapeutics investors own include CocaCola (KO), Cardium Therapeutics (CRXM), Anavex Life Sciences (AVXL), Sangamo Therapeutics (SGMO), Protalix BioTherapeutics (PLX) and Company Calendar Last Earnings5/15/2025Today6/04/2026Next Earnings (Estimated)8/17/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:BCLI CIK1137883 Webwww.brainstorm-cell.com Phone(201) 488-0460FaxN/AEmployees40Year Founded2004Profitability EPS (Trailing Twelve Months)($1.64) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$11.62 million Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-519.50% Debt Debt-to-Equity RatioN/A Current Ratio0.21 Quick Ratio0.21 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($1.36) per share Price / Book-0.58Miscellaneous Outstanding Shares11,035,000Free Float8,742,000Market Cap$8.75 million OptionableOptionable Beta0.30 Social Links 10 Stocks Set to Soar in 2026Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment. Get This Free Report This page (NASDAQ:BCLI) was last updated on 6/4/2026 by MarketBeat.com Staff. From Our PartnersTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredTrump’s secret China dealTrump just returned from Beijing with the most powerful business delegation in American history - Elon Musk, J...Porter & Company | SponsoredThe chokepoint supplier behind SpaceX's $1.75 trillion empireWhen Musk laughed and said 'you need transformers to run transformers,' it wasn't a joke - it was a confession...Behind the Markets | SponsoredMassive Data Leak Exposes 512,000-Line Code That Could Change Society Forever"You won't believe what I discovered at 4 World Trade Center" When our financial media correspondent travel...Chaikin Analytics | SponsoredYour $29.97 book is free todayWhy Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...Profits Run | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredMassive Update to My SpaceX IPO ThesisJeff Brown predicted SpaceX would be the biggest and most anticipated IPO ever - part of Elon's larger plan to...Brownstone Research | SponsoredYour 401k Is Exit LiquidityMichael Burry, who called the 2008 collapse, responded to a post by veteran Fidelity manager George Noble with...Americas Gold Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Brainstorm Cell Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Brainstorm Cell Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
